[Bevacizumab in thoracic oncology: results and practical aspects]

É Dansin; S Cousin; G Lauridant; B Mennecier

doi:10.1016/j.pneumo.2013.02.006

[Bevacizumab in thoracic oncology: results and practical aspects]

Rev Pneumol Clin. 2013 Jun;69(3):159-69. doi: 10.1016/j.pneumo.2013.02.006. Epub 2013 Apr 15.

[Article in French]

Authors

É Dansin¹, S Cousin, G Lauridant, B Mennecier

Affiliation

¹ Département de cancérologie générale, CLCC Oscar-Lambret, 3, rue Fréderic-Combemale, BP 307, 59020 Lille cedex, France. [email protected]

PMID: 23597632
DOI: 10.1016/j.pneumo.2013.02.006

Abstract

Bevacizumab (Avastin(®)) is the first antiangiogenic therapy approved in non-small cell lung cancer (NSCLC). It is also currently the only agent in this family approved in NSCLC. This review focuses on results of clinical trials assessing bevacizumab in thoracic oncology. It also provides to clinicians practical advices for its prescription.

Publication types

English Abstract
Review

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Bevacizumab
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Squamous Cell / drug therapy
Drug-Related Side Effects and Adverse Reactions / epidemiology
Drug-Related Side Effects and Adverse Reactions / therapy
Humans
Lung Neoplasms / drug therapy*
Medical Oncology
Professional Practice
Small Cell Lung Carcinoma / drug therapy
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bevacizumab